Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Equity Ratio (2022 - 2025)

Historic Equity Ratio for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to 0.83.

  • Entrada Therapeutics' Equity Ratio rose 833.02% to 0.83 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83, marking a year-over-year increase of 833.02%. This contributed to the annual value of 0.81 for FY2024, which is 5767.77% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Equity Ratio stood at 0.83, which was up 833.02% from 0.85 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Equity Ratio ranged from a high of 0.88 in Q1 2022 and a low of 0.42 during Q2 2023
  • Over the past 4 years, Entrada Therapeutics' median Equity Ratio value was 0.81 (recorded in 2024), while the average stood at 0.72.
  • As far as peak fluctuations go, Entrada Therapeutics' Equity Ratio plummeted by 5159.07% in 2023, and later skyrocketed by 7637.3% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Equity Ratio (Quarter) stood at 0.84 in 2022, then crashed by 38.75% to 0.52 in 2023, then skyrocketed by 57.68% to 0.81 in 2024, then increased by 1.31% to 0.83 in 2025.
  • Its Equity Ratio was 0.83 in Q3 2025, compared to 0.85 in Q2 2025 and 0.86 in Q1 2025.